Nitrosamine concerns for rifapentine and rifampicin
M
Nitrosamine impurities have been identified in rifapentine and rifampicin products.
First invitation of dexamethasone and remdesivir for Covid-19 published
M
The 1st Invitation to Manufacturers of therapeutics against COVID-19 to submit an Expression of Interest (EOI) for Product Evaluation was published today by the Prequalification Unit (PQT)
First rituximab similar biotherapeutic products prequalified
M
WHO Prequalification Unit (PQT) added the below new products to its prequalified list:
WHO Prequalification Unit – Medicines request to manufacturers to conduct risk assessments to evaluate the potential for the presence of nitrosamine impurities
M
Background
Medicine Regulatory Authorities firs
First meropenem prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
First biosimilar product prequalified
M
WHO Prequalification Team - Medicines (PQTm) added the below new product to its prequalified list:
Nitrosamine contamination – Recent international alerts
M
The WHO Prequalification Team (PQT) is aware, and monitoring closely, announcements by major regulators regarding the presence of nitrosamine impurities in batches of sartan-related products,
Product Recall - Moxifloxacin 100mg Dispersible Tablets (TB342): Batch BMC5801A
M
On 28 May 2019, Macleods Pharmaceutical Ltd.
Information on the GMP status of Micro Labs Kumbalgodu (ML08) manufacturing facility
M
A Good Manufacturing Practice (GMP) inspection of Micro Labs Ltd., Kumbalgodu (ML08) was carried out by the World Health Organization 27-31 August 2018.